- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03595358
Ellume·Lab Flu A+B Test and the Ellume Home Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction
A Prospective Multi-Centre Study of the Ellume·Lab Flu A+B Test and the Ellume Home Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction
The primary purpose of the study is to validate the sensitivity and specificity of the Ellume Home Flu Test and the ellume.lab Flu A+B Test in detecting influenza A and influenza B as compared to reverse transcriptase polymerase chain reaction (RT-PCR)
Secondary aims are to:
Validate the sensitivity and specificity of the Ellume Home Flu Test and the ellume.lab Flu A+B Test in detecting influenza A and influenza B as compared to viral culture; Evaluate the participant's satisfaction with the convenience and ease of use of the Ellume Home Flu Test; Evaluate the participant's interpretation of the Ellume Home Flu Test results compared to the interpretation by site staff; Evaluate the operator's satisfaction and ease of use of the ellume·lab Flu A+B Test.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Debbie Brezac
- Phone Number: +61 7 33931448
- Email: debbie.brezac@ellume.com.au
Study Locations
-
-
New South Wales
-
Kanwal, New South Wales, Australia, 2559
- Paratus Clinical Kanwal Trial Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female participants aged ≥ 2 years; and
- Fever ≥ 37.8° C (100° F) at presentation or history or parent/guardian-reported history of fever ≥ 37.8° C or feeling feverish within 24 hours of presentation; and
- Rhinorrhea; and
- ≤ 72 hours from onset of ILI symptoms; and
- Participant (or parent/legal guardian) capable and willing to give informed consent/assent; and
- Participant (or parent/legal guardian) able to read and write in English.
Exclusion Criteria:
- Participants aged < 2 years.
- Participants who have undergone treatment with Tamiflu (oseltamivir), Relenza (zanamivir) or Symmetral (amantadine) within the previous 7 days;
- Participants who have been vaccinated by means of an Influenza nasal spray/mist vaccine within the previous 7 days;
- Participants who have had a nose bleed within the past 30 days;
- Participants who have had recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months;
- Participants currently enrolled in another clinical trial or used any investigational device within 30 days preceding informed consent.
- Participants previously enrolled in IE-FLU-AUS-1801;
- Participants 18 years of age or older unable to understand English and consent to participation;
- Parent/legal guardian of participants < 18 years of age unable to understand English and consent to participation of child.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm
Ellume Home Flu Test and ellume.lab Flu A+B Test Upper respiratory tract samples from participants will be tested with: Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture. |
Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture.
In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
The Ellume Home Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples.
The ellume.lab
Flu A+B Test is a rapid in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples.
Reverse Transcriptase Polymerase Chain Reaction (RT_PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates.
The Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Of participants positive for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants positive for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by ellume.lab Flu A+B Test.
Time Frame: 1 day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by ellume.lab Flu A+B Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by ellume.lab Flu A+B Test.
Time Frame: 1 day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by ellume.lab Flu A+B Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Of participants positive for influenza A by viral culture, the percentage who are positive for influenza A by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants positive for influenza A by viral culture, the percentage who are positive for influenza A by ellume.lab Flu A+B Test.
Time Frame: 1day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1day
|
Of participants negative for influenza A by viral culture, the percentage who are negative for influenza A by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants negative for influenza A by viral culture, the percentage who are negative for influenza A by ellume.lab Flu A+B Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants positive for influenza B by viral culture, the percentage who are positive for influenza B by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence limits.
|
1 day
|
Of participants positive for influenza B by viral culture, the percentage who are positive for influenza B by ellume.lab Flu A+B Test.
Time Frame: 1 day
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants negative for influenza B by viral culture, the percentage who are negative for influenza B by Ellume Home Flu Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Of participants negative for influenza B by viral culture, the percentage who are negative for influenza B by ellume.lab Flu A+B Test.
Time Frame: 1 day
|
Establish specificity against a gold standard.
Report as a percentage of participants with 96% confidence intervals.
|
1 day
|
Percent of participants who correctly interpret the result of the Ellume Home Flu Test
Time Frame: 1 day
|
Agreement between trained staff and participants.
Report as a percentage of participants with 96% confidence limits.
|
1 day
|
Scores from questionnaire to assess ease of use, comfort and convenience of the Ellume Home Flu Test.
Time Frame: 1 day
|
The ease of use questionnaire will provide total number of responses to each question and the percentage of participants selecting each response (on a 5 point Likert scale).
|
1 day
|
Scores from questionnaire to assess ease of use and convenience of the ellume.lab Flu A+B Test.
Time Frame: 1 day
|
The ease of use questionnaire will provide total number of responses to each question and the percentage of participants selecting each response (on a 5 point Likert scale).
|
1 day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IE-FLU-AUS-1801
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Oxford; Wellcome Trust; World Health OrganizationCompletedInfluenza | Avian Influenza | Severe InfluenzaSingapore, Thailand, Vietnam
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on Viral culture
-
Kepler University HospitalCompleted
-
Becton, Dickinson and CompanyWithdrawn
-
Ellume Pty LtdCompleted
-
St. Jude Children's Research HospitalCompletedRespiratory Virus InfectionsUnited States
-
Bruce Shapiro M.D.Withdrawn
-
IVI SevillaCompleted
-
Federal University of São PauloIncept BiosystemsUnknown
-
Lindenwood UniversityCompletedImmune and Recovery Modulating Impact of Probiotic Supplementation After Intense Resistance ExerciseMuscle Damage | Muscular Fatigue | Immune Markers | Complete Blood Count (CBC) With Platelet Differentials | Muscular Force Production | Countermovement Jump | Muscular SorenessUnited States
-
Medical College of WisconsinWithdrawnAscites | Peritonitis
-
Forte Sports Medicine and OrthopedicsCompleted